Nanogen's Q4 Revenues Dip 3 Percent as Cash Dwindles | GenomeWeb

NEW YORK (GenomeWeb News) – Nanogen reported after market close on Friday that its fourth-quarter revenues decreased 3 percent, as the firm's cash reserves have dipped to $3.1 million.

The San Diego-based molecular diagnostics company released its preliminary results and said that it had deferred the audit of its financial statements for the year ended Dec. 31, 2008, in an effort to conserve cash. It noted that this move means it will not file its 10-K with the US Securities and Exchange Commission by the deadline of March 31.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.